7-117509135-A-G
Position:
Variant summary
Our verdict is Likely pathogenic. Variant got 6 ACMG points: 6P and 0B. PM1PM2PP3_Moderate
The ENST00000003084.11(CFTR):āc.266A>Gā(p.Tyr89Cys) variant causes a missense change. The variant allele was found at a frequency of 0.0000143 in 1,534,370 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (ā ā ).
Frequency
Genomes: š 0.000013 ( 0 hom., cov: 33)
Exomes š: 0.000014 ( 0 hom. )
Consequence
CFTR
ENST00000003084.11 missense
ENST00000003084.11 missense
Scores
11
5
3
Clinical Significance
Conservation
PhyloP100: 5.48
Genes affected
CFTR (HGNC:1884): (CF transmembrane conductance regulator) This gene encodes a member of the ATP-binding cassette (ABC) transporter superfamily. The encoded protein functions as a chloride channel, making it unique among members of this protein family, and controls ion and water secretion and absorption in epithelial tissues. Channel activation is mediated by cycles of regulatory domain phosphorylation, ATP-binding by the nucleotide-binding domains, and ATP hydrolysis. Mutations in this gene cause cystic fibrosis, the most common lethal genetic disorder in populations of Northern European descent. The most frequently occurring mutation in cystic fibrosis, DeltaF508, results in impaired folding and trafficking of the encoded protein. Multiple pseudogenes have been identified in the human genome. [provided by RefSeq, Aug 2017]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_pathogenic. Variant got 6 ACMG points.
PM1
In a hotspot region, there are 4 aminoacids with missense pathogenic changes in the window of +-8 aminoacids around while only 0 benign, 15 uncertain in ENST00000003084.11
PM2
Very rare variant in population databases, with high coverage;
PP3
MetaRNN computational evidence supports a deleterious effect, 0.904
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CFTR | NM_000492.4 | c.266A>G | p.Tyr89Cys | missense_variant | 3/27 | ENST00000003084.11 | NP_000483.3 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
CFTR | ENST00000003084.11 | c.266A>G | p.Tyr89Cys | missense_variant | 3/27 | 1 | NM_000492.4 | ENSP00000003084 | P2 |
Frequencies
GnomAD3 genomes AF: 0.0000131 AC: 2AN: 152164Hom.: 0 Cov.: 33
GnomAD3 genomes
AF:
AC:
2
AN:
152164
Hom.:
Cov.:
33
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.00000798 AC: 2AN: 250722Hom.: 0 AF XY: 0.00 AC XY: 0AN XY: 135544
GnomAD3 exomes
AF:
AC:
2
AN:
250722
Hom.:
AF XY:
AC XY:
0
AN XY:
135544
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000145 AC: 20AN: 1382206Hom.: 0 Cov.: 23 AF XY: 0.0000130 AC XY: 9AN XY: 692562
GnomAD4 exome
AF:
AC:
20
AN:
1382206
Hom.:
Cov.:
23
AF XY:
AC XY:
9
AN XY:
692562
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000131 AC: 2AN: 152164Hom.: 0 Cov.: 33 AF XY: 0.0000135 AC XY: 1AN XY: 74330
GnomAD4 genome
AF:
AC:
2
AN:
152164
Hom.:
Cov.:
33
AF XY:
AC XY:
1
AN XY:
74330
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
TwinsUK
AF:
AC:
1
ALSPAC
AF:
AC:
0
ExAC
AF:
AC:
1
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Uncertain significance
Submissions summary: Uncertain:7Other:1
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Cystic fibrosis Uncertain:3Other:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Feb 14, 2024 | The p.Y89C variant (also known as c.266A>G), located in coding exon 3 of the CFTR gene, results from an A to G substitution at nucleotide position 266. The tyrosine at codon 89 is replaced by cysteine, an amino acid with highly dissimilar properties. This variant was detected as heterozygous in in a male patient with chronic lung infection due to pseudomonas, diffuse bronchiectasis, pancreatic sufficiency, oligospermia, and multiple normal sweat tests; no second alteration was identified (Padoan R et al. Hum Mutat, 2000 May;15:486). Functional studies show that Y89C alteration had a glycosylation pattern and a subcellular distribution comparable to wild-type CFTR, but may still impact channel gating; however, the clinical significance of these findings is unclear (Gené GG et al. Hum Mutat, 2008 May;29:738-49). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the available evidence, the clinical significance of this alteration remains unclear. - |
not provided, no classification provided | literature only | ClinVar Staff, National Center for Biotechnology Information (NCBI) | - | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jul 14, 2022 | This sequence change replaces tyrosine, which is neutral and polar, with cysteine, which is neutral and slightly polar, at codon 89 of the CFTR protein (p.Tyr89Cys). This variant is present in population databases (rs397508418, gnomAD 0.003%). This missense change has been observed in individual(s) with clinical features of CFTR-related conditions (PMID: 10790225, 17272608, 26098992). ClinVar contains an entry for this variant (Variation ID: 53541). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Johns Hopkins Genomics, Johns Hopkins University | Jul 14, 2023 | This CFTR missense variant (rs397508418) is rare (<0.1%) in a large population dataset (gnomADv2.1.1: 2/250722 total alleles; 0.0008%; no homozygotes) and has been reported in ClinVar (Variation ID:53541). It has not been reported in the literature in individuals with features of cystic fibrosis who have a second CF-causing variant, to our knowledge. Two bioinformatic tools queried predict that this substitution would be damaging and a single functional study suggests that this variant may impact CFTR gating. The tyrosine residue at this position is evolutionarily conserved across all species assessed except one. We consider the clinical significance of CFTR c.266A>G to be uncertain at this time. - |
not provided Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Feb 20, 2020 | The CFTR c.266A>G; p.Tyr89Cys variant (rs397508418) is reported in the literature in the heterozygous state without a second CFTR variant identified in individuals affected with cystic fibrosis or CFTR-related disorders (Giusti 2007, Padoan 2000). This variant is reported in ClinVar (Variation ID: 53541), and is only observed on one allele in the Genome Aggregation Database, indicating it is not a common polymorphism. The tyrosine at codon 89 is highly conserved, and computational analyses (SIFT, PolyPhen-2) predict that this variant is deleterious. Functional analyses of the variant protein show normal maturation and trafficking, but some alterations to channel gating (Gene 2008). Due to limited information, the clinical significance of the p.Tyr89Cys variant is uncertain at this time. References: Gene GG et al. N-terminal CFTR missense variants severely affect the behavior of the CFTR chloride channel. Hum Mutat. 2008 May;29(5):738-49. Giusti R et al. New York State cystic fibrosis consortium: the first 2.5 years of experience with cystic fibrosis newborn screening in an ethnically diverse population. Pediatrics. 2007 Feb;119(2):e460-7. Padoan R et al. A novel missense mutation (Y89C) in exon 3 of the CFTR (ABCC7) gene in a young male. Hum Mutat. 2000 May;15(5):486. - |
Uncertain significance, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Feb 01, 2023 | CFTR: PM2, PP3 - |
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Oct 02, 2023 | Variant summary: CFTR c.266A>G (p.Tyr89Cys) results in a non-conservative amino acid change located in the ABC transporter type 1, transmembrane domain (IPR011527) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 8e-06 in 250722 control chromosomes (gnomAD). The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. c.266A>G has been reported in the literature as a non-informative genotype (second allele not specified) among individuals with non-classic features of Cystic Fibrosis and in at-least one newborn with features of Cystic Fibrosis (example, Giusti_2007, Padoan_2000, Straniero_2016). These data do not allow any conclusion about variant significance. At least one publication reports experimental evidence evaluating an impact on protein function, however, does not allow convincing conclusions about the variant effect despite the authors reporting a glycosylation pattern and a subcellular distribution comparable to WT-CFTR suggesting they might reach the plasma membrane. Single channel patch clamp analysis revealed that this variant displayed abnormal gating but authors suggested that additional studies are needed to corroborate these equivocal findings (Gene_2008). The following publications have been ascertained in the context of this evaluation (PMID: 18306312, 17272608, 10790225, 27488443, 26098992). Five submitters have cited clinical-significance assessments for this variant to ClinVar after 2014. All submitters classified the variant as uncertain significance. Based on the evidence outlined above, the variant was classified as uncertain significance. - |
CFTR-related disorder Uncertain:1
Uncertain significance, no assertion criteria provided | clinical testing | Natera, Inc. | Jul 02, 2018 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Uncertain
DANN
Uncertain
DEOGEN2
Pathogenic
.;D;.;.;T;.
Eigen
Uncertain
Eigen_PC
Uncertain
FATHMM_MKL
Uncertain
D
LIST_S2
Uncertain
D;D;D;D;D;D
M_CAP
Pathogenic
D
MetaRNN
Pathogenic
D;D;D;D;D;D
MetaSVM
Pathogenic
D
MutationAssessor
Benign
.;L;.;.;.;L
MutationTaster
Benign
D;D
PrimateAI
Pathogenic
T
PROVEAN
Pathogenic
D;D;.;.;D;.
REVEL
Pathogenic
Sift
Pathogenic
D;D;.;.;D;.
Sift4G
Pathogenic
D;D;.;.;D;.
Polyphen
1.0
.;D;.;.;.;.
Vest4
0.91
MVP
MPC
0.0043
ClinPred
D
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at